Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;23(8):647-649.
doi: 10.1080/14728222.2019.1628220. Epub 2019 Jun 5.

Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment

Rajan Patel  1 , Jeffrey I Traylor  1 , Khatri Latha  1 , Amy B Heimberger  1 , Shulin Li  2 , Ganesh Rao  1
Affiliations
Editorial

Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment

Rajan Patel et al. Expert Opin Ther Targets. 2019 Aug.
No abstract available

Keywords: FGL2; glioblastoma multiforme; low grade glioma; progression.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1:
Figure 1:
Schematic of FGL2 function. FGL2 activates the FcγRIIB on antigen presenting cells (APC) which can override PD1 (programmed cell death) blockade, resulting in T-cell inactivation. FcγRIIB blockade will subsequently result in T-cell activation in conjunction with anti-PD1 antibody therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Latha K, Yan J, Yang Y, et al. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. Journal of the National Cancer Institute. 2019;111(3):292–300.

      **Latha et al. and showed that FGL2 is a key molecule in the progression of low-grade glioma to high-grade glioma.

    1. Yan J, Zhao Q, Gabrusiewicz K, et al. FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nature communications. 2019;10(1):448. - PMC - PubMed

    1. Chan CW, Kay LS, Khadaroo RG, et al. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. Journal of immunology (Baltimore, Md : 1950). 2003;170(8):4036–4044.

      **Chan et al. reported that FGL2 exerts immunosuppressive effects on the proliferation of T-cells as well as the maturation of dendritic cells.

    1. Luft O, Khattar R, Farrokhi K, et al. Inhibition of the Fibrinogen-Like Protein 2:FcgammaRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13. Immunology. 2018;154(3):476–489. - PMC - PubMed
    1. Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. 2018;379(8):722–730. - PMC - PubMed

Publication types